GSK delivers improvements in sales, margins and cash flow in 2017
8y agoen
From the article
Total EPS 31.4p, +67% AER, +36% CER; Adjusted EPS 111.8p, +11% AER, +4% CER
Continue reading on GSKYou might also wanna read
Keenova eyes Xiaflex as first drug for plantar fibromatosis
pharmaphorum·1h ago
GSK ends dementia alliance with Alector after setbacks
pharmaphorum·2h ago
NICE aims to cut funding for Amgen lung cancer drug Lumykras
pharmaphorum·3h ago
Is pure play pharma's new pharmakon?
pharmaphorum·3h ago
Roy Jakobs to join GSK Board as Non-Executive Director
GSK·3h ago
AZ, Ionis hit by unexpected Wainua trial failure
pharmaphorum·4h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.